Key result
GLP-1 receptor agonist study yields no quantitative results regarding Parkinson's disease risk.
Why the study?
Do Glucagon-Like Peptide-1 Receptor Agonists affect the risk of Parkinson's Disease in patients with obesity and without type 2 diabetes?
Observational
Do Glucagon-Like Peptide-1 Receptor Agonists affect the risk of Parkinson's Disease in patients with obesity and without type 2 diabetes?
Examines the impact of GLP-1 receptor agonists on Parkinson's disease risk in obese individuals without diabetes, suggesting potential protective effects.
This work is supported by the National Institutes of Health (NIH), including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01DK133465), and additional NIH grants (U01AG088076, RF1AG077820, R01AG083039, R01AG080991, R01AG084236 and R01AG076234). There are no other relevant financial disclosures relevant to this work. The authors declare no conflicts of interest. Data set is available through individual requests on OneFlorida+ Clinical Research Network (email, onefloridaoperations@health.ufl.edu). The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70904.
No takes yet. Share an insight, caveat, or question.
Kotecha et al. (2026) conducted an observational in Obesity without Type 2 Diabetes. Glucagon-Like Peptide-1 Receptor Agonists was evaluated on Parkinson's Disease. The provided abstract contains only funding and data availability statements, yielding no quantitative results regarding GLP-1 receptor agonists and Parkinson's disease risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: